ATA-200
/ Atamyo Therap
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
February 14, 2025
ATA-200 Dose-escalation Gene Therapy Trial in Patients with LGMDR5
(clinicaltrials.gov)
- P1/2 | N=6 | Recruiting | Sponsor: Atamyo Therapeutics | Not yet recruiting ➔ Recruiting
Enrollment open • Gene Therapies
July 31, 2024
ATA-200 Dose-escalation Gene Therapy Trial in Patients With LGMDR5
(clinicaltrials.gov)
- P1/2 | N=6 | Not yet recruiting | Sponsor: Atamyo Therapeutics | Trial completion date: Jun 2030 ➔ Dec 2031 | Trial primary completion date: Dec 2025 ➔ Jun 2026
Gene therapy • Trial completion date • Trial primary completion date • Viral vector • Gene Therapies
January 29, 2024
ATA-200 Dose-escalation Gene Therapy Trial in Patients With LGMDR5
(clinicaltrials.gov)
- P1/2 | N=6 | Not yet recruiting | Sponsor: Atamyo Therapeutics | Initiation date: Jan 2024 ➔ May 2024
Gene therapy • Trial initiation date • Viral vector • Gene Therapies
August 03, 2023
ATA-200 Dose-escalation Gene Therapy Trial in Patients With LGMDR5
(clinicaltrials.gov)
- P1/2 | N=6 | Not yet recruiting | Sponsor: Atamyo Therapeutics
Gene therapy • New P1/2 trial • Viral vector • Gene Therapies • Muscular Dystrophy
1 to 4
Of
4
Go to page
1